After an apparent cure, a gene editing company struggles to repeat the magicnews2026-05-13T18:50:53+00:00May 13th, 2026|Endpoints News|
Tessera reveals strongest data yet for in vivo sickle cell therapynews2026-05-13T12:00:56+00:00May 13th, 2026|Endpoints News|
Flagship startup Serif says it has solved non-viral gene therapy in monkeysnews2026-05-12T10:00:42+00:00May 12th, 2026|Endpoints News|
European regulators greenlight Fractyl Health’s clinical test of GLP-1 gene therapynews2026-05-11T11:00:40+00:00May 11th, 2026|Endpoints News|
Atara, Pierre Fabre’s cell therapy to get another shot at FDA approvalnews2026-05-07T13:17:55+00:00May 7th, 2026|Endpoints News|
Former Orbital scientists launch new mRNA therapy startupnews2026-05-06T15:17:04+00:00May 6th, 2026|Endpoints News|
J&J axes pair of CAR-T therapies for lymphoma, citing evolving marketnews2026-05-01T11:07:45+00:00May 1st, 2026|Endpoints News|
Lilly strikes second partnership this year for recombinase-based gene editingnews2026-04-28T11:00:57+00:00April 28th, 2026|Endpoints News|
Intellia’s in vivo CRISPR therapy first to succeed in Phase 3news2026-04-27T11:01:29+00:00April 27th, 2026|Endpoints News|
Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapynews2026-04-24T14:00:16+00:00April 24th, 2026|Endpoints News|
